Paper40445936
Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19.
Yan H and 8 others. PLoS One, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19. Papers, record 40445936. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40445936
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 Drug Treatment | Major topic |
| Immunosuppressive Agents | Major topic |
| Kidney Transplantation | Major topic |
| Ritonavir | Major topic |
| Tacrolimus | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| COVID-19 | |
| Drug Therapy, Combination | |
| Retrospective Studies | |
| SARS-CoV-2 | |
| Transplant Recipients |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32382127 | NKG2A and COVID-19: another brick in the wall. | Cell Mol Immunol | 2020 | https://conductscience.org/library/papers/32382127 | PubMed |
| 2 | 33278850 | Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: A nationwide population-based study. | Am J Transplant | 2021 | https://conductscience.org/library/papers/33278850 | PubMed |
| 3 | 35713302 | Single-center experience with nirmatrelvir/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression. | Clin Transplant | 2022 | https://conductscience.org/library/papers/35713302 | PubMed |
| 4 | 35618549 | Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT). | Therapie | 2022 | https://conductscience.org/library/papers/35618549 | PubMed |
| 5 | 35816278 | Paxlovid-Tacrolimus Drug-Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19. | Clin Drug Investig | 2022 | https://conductscience.org/library/papers/35816278 | PubMed |
| 6 | 25386767 | An interferon-free antiviral regimen for HCV after liver transplantation. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25386767 | PubMed |
| 7 | 33246166 | COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. | Transplant Rev (Orlando) | 2021 | https://conductscience.org/library/papers/33246166 | PubMed |
| 8 | 37477905 | Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS. | Expert Opin Drug Saf | 2023 | https://conductscience.org/library/papers/37477905 | PubMed |
| 9 | 35653428 | Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. | Clin Infect Dis | 2023 | https://conductscience.org/library/papers/35653428 | PubMed |
| 10 | 33101306 | Covid-19: Perspectives on Innate Immune Evasion. | Front Immunol | 2020 | https://conductscience.org/library/papers/33101306 | PubMed |
| 11 | 35944126 | Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19. | Ther Drug Monit | 2023 | https://conductscience.org/library/papers/35944126 | PubMed |
| 12 | 21937987 | Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. | Clin Pharmacol Ther | 2011 | https://conductscience.org/library/papers/21937987 | PubMed |
| 13 | 35172054 | Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35172054 | PubMed |
| 14 | 33988341 | Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network. | Transplantation | 2021 | https://conductscience.org/library/papers/33988341 | PubMed |
| 15 | 36847419 | "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time". | Transpl Infect Dis | 2023 | https://conductscience.org/library/papers/36847419 | PubMed |
| 16 | 34695836 | Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. | Nature | 2021 | https://conductscience.org/library/papers/34695836 | PubMed |
| 17 | 35599203 | Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report. | Transplant Proc | 2022 | https://conductscience.org/library/papers/35599203 | PubMed |
| 18 | 34017137 | CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. | Nat Med | 2021 | https://conductscience.org/library/papers/34017137 | PubMed |
| 19 | 25708713 | Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. | Am J Transplant | 2015 | https://conductscience.org/library/papers/25708713 | PubMed |
| 20 | 34087553 | The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis. | Transplant Rev (Orlando) | 2021 | https://conductscience.org/library/papers/34087553 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42965158 | Drug Rescue for Paxlovid-Induced Tacrolimus Toxicity: A Pooled Analysis of Case Reports. | Kidney Med | 2026 | https://conductscience.org/library/papers/42965158 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40445936
GET https://conductscience.org/api/papers/v1/40445936/references?page=2